Alymsys (bevacizumab-maly) vs HD204

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Alymsys (bevacizumab-maly)

Marketed by Amneal Pharmaceuticals

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

HD204

Developed by Intas Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03390686 · Phase 3 · active, not recruiting

This was a randomised, double-blind, active-controlled Phase 3 equivalence trial (625 patients randomised, per the sponsor) comparing HD204 with reference bevacizumab (Avastin), each with chemotherapy, in advanced non-squamous NSCLC. The primary endpoint was objective response rate at week 18, and the prespecified equivalence margin test succeeded (risk ratio 1.047, 95% CI 0.86 to 1.27), showing clinical equivalence with the reference product.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor's topline release reports 625 patients randomised 1:1; the registry lists 650 enrolled.

Reported efficacy

Overall Response Rate (ORR) at Week 18 (18 weeks from randomization): SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin (met)

Result source: NCT03390686

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlymsys (bevacizumab-maly)HD204
PFS, median8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163—Trial running · NCT03390686
OS, median—Not reported—Trial running · NCT03390686
ORR40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163—Trial running · NCT03390686
Duration of response, median—Not reported—Trial running · NCT03390686

PFS, median

Alymsys (bevacizumab-maly)
8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163
HD204
—Trial running · NCT03390686

OS, median

Alymsys (bevacizumab-maly)
—Not reported
HD204
—Trial running · NCT03390686

ORR

Alymsys (bevacizumab-maly)
40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163
HD204
—Trial running · NCT03390686

Duration of response, median

Alymsys (bevacizumab-maly)
—Not reported
HD204
—Trial running · NCT03390686
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HD204
SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin NCT03390686 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · HD204: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlymsys (bevacizumab-maly)
Dropout rate
34.3%a
NCT03296163 · Phase 3
Discontinued due to AEs
—a
NCT03296163 · Phase 3
Serious AEs
18.6%a
NCT03296163 · Phase 3
Most frequent reported AEs
a
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alymsys (bevacizumab-maly)

ORR 40.3% (n=315) vs 44.6% (n=312) Avastin @ 18wk
responder rate · % of participants
NCT03296163 · Phase 3
PFS 8.31 vs 8.61 Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3 · converted to months from 36 weeks as posted
Overall Survival NA vs NA Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · HD204's landscape